CARMAT

CARMAT
Name	CARMAT
Type	Public
Industry	Medical devices
Founded	2008
Founder	Alain Carpentier
Headquarters	France
Key people	Alain Carpentier, Bernard Croquette
Products	Artificial heart

CARMAT is a French biomedical company that developed a total artificial heart intended as a long-term circulatory support device for patients with end-stage biventricular heart failure. The project combines expertise from cardiovascular surgery, biotechnology, materials science, and regulatory medicine and involved collaborations with academic institutions, hospitals, and industrial partners across France, United States, and European Union centers. The program attracted attention from clinicians involved in heart transplantation, mechanical circulatory support, and bioengineering at institutions such as Hôpital Européen Georges-Pompidou, Harvard Medical School, and regulatory agencies like the European Medicines Agency.

History

The company was founded by cardiac surgeon Alain Carpentier in 2008 after decades of research into prosthetic valves and cardiac reconstruction inspired by surgical innovations at Hôpital Bichat–Claude Bernard and clinical networks including Assistance Publique–Hôpitaux de Paris. Early development drew intellectual inheritance from work at École Polytechnique and collaborations with engineering groups at CEA and industrial partners in France. Initial financing combined venture capital, research grants from Agence Nationale de la Recherche, and strategic partnerships with medical device investors in Paris and London. The program progressed from preclinical studies in large-animal models at veterinary and translational research centers affiliated with INSERM and universities, to first-in-human implantation at tertiary referral centers such as Hôpital Européen Georges-Pompidou and trial sites across France and Czech Republic.

Design and Technology

The prosthesis integrates a bioprosthetic valve lineage pioneered by its founder with engineering approaches used by teams at Massachusetts Institute of Technology and ETH Zurich. The device uses bovine pericardial tissue, a pneumatic-hydraulic actuation system influenced by work from Stanford University and Delft University of Technology, and sensors for flow and pressure developed with microelectronics groups that have collaborated with CEA-Leti and startups from Silicon Valley. Materials science contributions trace to research from CNRS laboratories and biomaterials groups at University of Cambridge and Karolinska Institutet. The housing employs hemocompatible coatings inspired by techniques used in vascular grafts at Johns Hopkins University, and the control algorithms draw on real-time control theory applied in projects at Imperial College London and California Institute of Technology. The integrated system aims to replicate biventricular physiology while minimizing thrombosis risk and enabling physiologic responsiveness to patient activity levels.

Clinical Trials and Regulatory Approval

Initial human implantations occurred under compassionate use protocols overseen by institutional review boards at major transplant centers including Hôpital Pitié-Salpêtrière and were conducted in coordination with regulatory authorities such as the French National Agency for Medicines and Health Products Safety and the European Medicines Agency. Subsequent prospective, multicenter clinical trials registered at national databases involved sites across France, Czech Republic, and other European countries, and engaged multidisciplinary teams from Université Paris Cité, Charles University, and university hospitals affiliated with AP-HP. The path to market included interactions with national competent authorities, conformity assessments under CE marking procedures, and comparative discussions involving cardiac registries like those maintained by European Society of Cardiology and transplant registries such as Eurotransplant.

Manufacturing and Commercialization

Production scaled through partnerships with medical manufacturing firms in Île-de-France and precision engineering suppliers in Auvergne-Rhône-Alpes. Quality systems were implemented in line with standards from International Organization for Standardization and device directives applied by notified bodies in European Union markets. Commercialization efforts targeted specialized cardiac centers and transplant programs, building service networks similar to distribution models used by global device companies such as Medtronic and Abbott Laboratories. Strategic alliances explored expansion into markets regulated by agencies like the U.S. Food and Drug Administration and health technology assessment processes in countries including Germany and United Kingdom.

Performance and Outcomes

Clinical reports and observational data presented at congresses of the European Association for Cardio-Thoracic Surgery and American Heart Association described patient outcomes including bridging to transplantation and long-term support durations comparable to other mechanical circulatory support options. Outcomes analyses referenced metrics familiar to transplant and heart-failure communities, such as survival, device-related adverse events, and functional status measured using classifications developed by New York Heart Association. Comparative discussions considered experiences from long-term ventricular assist device programs at centers like Cleveland Clinic, Mayo Clinic, and Johns Hopkins Hospital. Peer-reviewed case series examined hemocompatibility profiles, incidence of stroke, infection rates, and device durability in the context of historical data from total artificial heart development efforts including early work at Pennsylvania Hospital and engineering projects at University of Utah.

Controversies and Challenges

Debate in clinical and regulatory circles involved patient selection, ethical considerations reminiscent of early bioengineering controversies at institutions such as Rockefeller University, and cost-effectiveness discussions similar to debates around high-cost technologies evaluated by agencies like National Institute for Health and Care Excellence. Operational challenges included supply-chain constraints in precision components sourced from specialized suppliers in Germany and Italy, reimbursement negotiations with health payers in France and Belgium, and the technical challenge of reducing thromboembolic complications noted in historical mechanical circulatory support literature from Duke University and University of Pennsylvania. Public and professional scrutiny occurred in forums including meetings of the European Society of Cardiology and national health technology assessment panels.

Category:Medical device companies